In a high-risk cohort, a new-found checkpoint NRP1 (neuropilin-1) was reported as an immune response suppressor to cancer gathered higher expression [22], as well as CD276 [23], which was proven to participate in tumor immune evasion in HNSCC. This evidence concerns the gene CD276 and cancer.